Irisin levels in type 2 diabetes mellitus with and without non-alcoholic fatty liver disease:  a case-control study

Saffalya Nayak; Pratima Kumari Sahu; Roma Rattan; Srikrushna Mahapatra; Debjyoti Mohapatra

doi:10.56782/pps.254

Published : 2024-09-26

Vol. 22 No. 3 (2024)

Irisin levels in type 2 diabetes mellitus with and without non-alcoholic fatty liver disease: a case-control study

Saffalya Nayak

Pratima Kumari Sahu

Roma Rattan

Srikrushna Mahapatra

Debjyoti Mohapatra

DOI: https://doi.org/10.56782/pps.254

Abstract

Background: Fatty liver disease, particularly non-alcoholic fatty liver disease (NAFLD), affects around 25% of adults globally and up to 40% in developed countries. Often coexisting with type 2 diabetes mellitus (T2DM), NAFLD is linked to insulin resistance and metabolic syndrome. Irisin, a myokine induced by exercise, shows promise in enhancing insulin sensitivity, reducing hepatic steatosis, and improving metabolic health. Despite its potential, further research is needed to fully understand irisin's mechanisms and clinical implications in NAFLD and T2DM.

Objectives: This study investigates the irisin levels in T2DM patients with and without NAFLD and compares them with healthy controls.

Methods: A case-control study has been conducted involving 90 T2DM patients and 90 healthy controls, aged 30-55 years, recruited from SCB Medical College, Cuttack, between September 2021 and August 2022. Participants were screened for NAFLD using the Hepatosis Steatosis Index (HSI) and divided into four groups: T2DM with NAFLD, T2DM without NAFLD, controls with NAFLD, and controls without NAFLD. Serum irisin levels were measured using ELISA. Anthropometric data, physical activity, and various biochemical parameters were assessed and analyzed.

Results: The irisin levels were significantly lower in T2DM patients compared to healthy controls
(p = 0.001). Among T2DM patients, those with NAFLD had lower irisin levels than those without NAFLD, though not statistically significant (p = 0.299). Significant correlations were observed between irisin levels and insulin sensitivity markers such as HOMA-IR and QUICKI across different groups.

Conclusion: Lower irisin levels in T2DM patients, particularly those with NAFLD, highlight its potential role in the pathogenesis of metabolic disorders. Further research is needed to elucidate irisin's therapeutic implications in T2DM and NAFLD.

Keywords:

Irisin, Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, Insulin Sensitivity

Similar Articles

Sükrü Canpolat, Cihan Düşgün, Elif Ildız, Elif Yürümez Canpolat, Cemil İşlek, Antioxidant potential and fatty acid composition of Lactarius sanguifluus , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Anna Król, THE ROLE OF IMMUNE CELLS IN THE PATHOGENESIS OF GRAVES' ORBITOPATHY , Prospects in Pharmaceutical Sciences: Vol. 17 No. 3 (2019)
Jadwiga Piwowarska, Jolanta Felczak, Jacek Łukaszkiewicz, CONCENTRATION OF MALONDIALDEHYDE IN BLOOD AS AN INDICATOR IN LIVER TRANSPLANTATION , Prospects in Pharmaceutical Sciences: Vol. 14 No. 6 (2016)
Małgorzata Krzyżanowska, Katarzyna Kozon, Jakub Olszewski, Andrzej Patyra, Efficacy of satralizumab therapy in the treatment of NMOSD , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
Jakub Olszewski, Katarzyna Kozon, Magdalena Sitnik, Katarzyna Herjan, Karolina Mikołap, Bartłomiej Gastoł, Maciej Bara, Piotr Armański, Marcin Sawczuk, Mirikizumab – a new option in the treatment of inflammatory bowel diseases , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Katarzyna Kozon, Małgorzata Krzyżanowska, Jakub Olszewski, Andrzej Patyra, Spinal muscular atrophy – the effectiveness of treatment and new therapeutic possibilities for selected groups of patients in Poland , Prospects in Pharmaceutical Sciences: Vol. 21 No. 2 (2023)
Małgorzata Jelińska, FATTY ACIDS - CARCINOGENESIS MODIFYING FACTORS , Prospects in Pharmaceutical Sciences: Vol. 3 No. 1 (2005)
Girish B S, Srinivasan R, Joel M. Johns, C S Meghana, Adaptability of clinical pharmacist led interventions in the management of anemia of chronic renal disease: optimizing care , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Nazan Comlekcioglu, Ashabil Aygan, Mustafa Sevindik, Uğur Comlekcioglu, Comparative analysis of phytochemical properties of extracts obtained from flowers and leaves of Astragalus angustifolius collected from different locations , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Falah Saleh Mohammed, İmran Uysal, Mustafa Sevindik, A review on antiviral pants effective against different virus types , Prospects in Pharmaceutical Sciences: Vol. 21 No. 2 (2023)

<< < 1 2 3 4 5 6 7 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF

Citation rules

Nayak, S., Sahu, P. K., Roma Rattan, Mahapatra, S., & Mohapatra, D. (2024). Irisin levels in type 2 diabetes mellitus with and without non-alcoholic fatty liver disease: a case-control study. Prospects in Pharmaceutical Sciences, 22(3), 210–218. https://doi.org/10.56782/pps.254

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Dharmalingam, M.; Yamasandhi, P.G. Nonalcoholic fatty liver disease and Type 2 diabetes mellitus. Indian J. Endocrinol. Metab. 2018, 22, Art. No: 421. DOI: 10.4103/ijem.IJEM_585_17 DOI: https://doi.org/10.4103/ijem.IJEM_585_17

Boström, P.; Wu, J.; Jedrychowski, M.P.; Korde, A.; Ye, L.; Lo, J.C.; et al. A PGC1α-dependent myokine that drives browning of white fat and thermogenesis. Nature 2011, 481, 463–468. DOI: 10.1038/nature10777 DOI: https://doi.org/10.1038/nature10777

Zhang, T.; Yi, Q.; Huang, W.; Feng, J.; Liu, H. New insights into the roles of Irisin in diabetic cardiomyopathy and vascular diseases. Biomed. Pharmacother. 2024, 175, Art. No: 116631. DOI: 10.1016/j.biopha.2024.116631 DOI: https://doi.org/10.1016/j.biopha.2024.116631

Hu, J.; Ke, Y.; Wu, F.; Liu, S.; Ji, C.; Zhu, X.; et al. Circulating Irisin Levels in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterol. Res. Pract. 2020, 2020, Art. No: 8818191. DOI: 10.1155/2020/8818191 DOI: https://doi.org/10.1155/2020/8818191

Hou, N.; Liu, Y.; Han, F.; et al. Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice. J. Mol. Cell. Cardiol. 2016, 99, 188–196. DOI: 10.1016/j.yjmcc.2016.09.005 DOI: https://doi.org/10.1016/j.yjmcc.2016.09.005

Zhang, Y.; Li, R.; Meng, Y.; et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes 2014, 63, 514–525. DOI: 10.2337/db13-1106 DOI: https://doi.org/10.2337/db13-1106

Wang, C.; Wang, L.; Li, W.; et al. Irisin has no effect on lipolysis in 3T3-L1 adipocytes or fatty acid metabolism in HepG2 hepatocytes. Endocrine 2015, 49, 90–96. DOI: 10.1007/s12020-014-0458-9 DOI: https://doi.org/10.1007/s12020-014-0458-9

Zhang, H.J.; Zhang, X.F.; Ma, Z.M.; Pan, L.L.; Chen, Z.; et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J. Hepatol. 2013, 59, 557–562. DOI: 10.1016/j.jhep.2013.04.030 DOI: https://doi.org/10.1016/j.jhep.2013.04.030

Polyzos, S.A.; Kountouras, J.; Anastasilakis, A.D.; Geladari, E.V.; Mantzoros, C.S. Irisin in patients with nonalcoholic fatty liver disease. Metabolism 2014, 63, 207–217. DOI: 10.1016/j.metabol.2013.09.013

World Health Organization. Diagnosis and management of type 2 diabetes (HEARTS-D). Geneva: World Health Organization; 2020. WHO/UCN/NCD/20.1. Available online: https://www.who.int/publications/i/item/9789240062147 (accessed on 9 August 2019).

World Health Organization. Global Physical Activity Questionnaire (GPAQ) Analysis Guide. Geneva: World Health Organization; 2016. Available online: https:// www.who.int/publications/m/item/global-physical-activity-questionnaire (accessed on 9 August 2019).

Kosmalski, M.; Drzewoski, J.; Szymczak-Pajor, I.; Zieleniak, A.; Mikołajczyk-Solińska, M.; Kasznicki, J.; Śliwińska, A. Irisin is related to non-alcoholic fatty liver disease (NAFLD). Biomedicines 2022, 10, Art. No: 2253. DOI: 10.3390/biomedicines10092253 DOI: https://doi.org/10.3390/biomedicines10092253

Bazick, J.; Donithan, M.; Neuschwander Tetri, B.A.; Kleiner, D.; Brunt, E.M.; Wilson, L.; et al. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: Guidelines for referral in NAFLD. Diabetes Care 2015, 38, 1347–1355. DOI: https://doi.org/10.2337/dc14-1239

Lee, J.H.; Kim, D.; Kim, H.J.; et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig. Liver Dis. 2010, 42, 503–508. DOI: 10.1016/j.dld.2009.08.002 DOI: https://doi.org/10.1016/j.dld.2009.08.002

Jiang, Z.G.; de Boer, I.H.; Mackey, R.H.; et al. Associations of insulin resistance, inflammation and liver synthetic function with very low-density finlipoprotein: The Cardiovascular Health Study. Metabolism 2016, 65, 92–99. DOI: 10.1016/j.metabol.2015.10.017 DOI: https://doi.org/10.1016/j.metabol.2015.10.017

Shanaki, M.; Moradi, N.; Emamgholipour, S.; Fadaei, R.; Poustchi, H. Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes. Diabetes Metab. Syndr. 2017, 11, S467–S472. DOI: https://doi.org/10.1016/j.dsx.2017.03.037

Choi, E.S.; Kim, M.K.; Song, M.K.; et al. Association between serum irisin levels and non-alcoholic fatty liver disease in health screen examinees. PLoS One 2014, 9, Art. No: e110680. DOI: https://doi.org/10.1371/journal.pone.0110680

Mahmoodnia, L.; Sadoughi, M.; Ahmadi, A.; Kafeshani, M. Relationship between serum irisin, glycemic indices, and renal function in type 2 diabetic patients. J. Renal Inj. Prev. 2017, 6, 88–92. DOI: 10.15171/jrip.2017.17 DOI: https://doi.org/10.15171/jrip.2017.17

Wen, M.S.; Wang, C.Y.; Lin, S.L.; Hung, K.C. Decrease in irisin in patients with chronic kidney disease. PLoS One 2013, 8, Art. No: e64025. DOI: https://doi.org/10.1371/journal.pone.0064025

Liu, J.J.; Liu, S.; Wong, M.D.; Tan, C.S.; Tavintharan, S.; Sum, C.F.; et al. Relationship between circulating irisin, renal function and body composition in type 2 diabetes. J. Diabetes Complicat. 2014, 28, 208–213. DOI: 10.1016/j.jdiacomp.2013.09.011 DOI: https://doi.org/10.1016/j.jdiacomp.2013.09.011

Ma, Y.; Wu, X.; Liu, X.; et al. Expression of irisin in liver tissue of patients with nonalcoholic fatty liver disease. J. Zhengzhou Univ. 2016, 51, 517–520.

Park, K.H.; Zaichenko, L.; Brinkoetter, M.; et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J. Clin. Endocrinol. Metab. 2013, 98, 4899–4907. DOI: https://doi.org/10.1210/jc.2013-2373

Saffalya Nayak

nayaksaffalya@gmail.com

Affiliation:

a:1:{s:5:"en_US";s:33:"SCB Medical College and Hospital ";} India

Pratima Kumari Sahu

drpratimasahu@gmail.com

Affiliation:

SCB Medical College and Hospital India

Bio Statement (e.g., department and rank)

Head of The Department,SCB Medical College and Hospital,Cuttack,Odisha,India

Roma Rattan

drrattanroma@gmail.com

Affiliation:

Directorate of Medical Education,Odisha India

Bio Statement (e.g., department and rank)

Joint DMET

Srikrushna Mahapatra

srikrushna.mahapatra@gmail.com

Affiliation:

Kalinga Institute of Medical Sciences,Bhubaneswar,Odisha India

Bio Statement (e.g., department and rank)

Head of the Department,Biochemistry

Debjyoti Mohapatra

drdebjyoti@gmail.com

Affiliation:

SJ Medical College and Hospital,Puri,Odisha,India India

Bio Statement (e.g., department and rank)

Assistant Professor